Metformin Testing Prompts New Finding Of NDMA And Cancer Risk
FDA Asks Several Manufacturers To Recall Products In US
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.
